14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Effect of PLC- β1/CaM signaling pathway mediated by AT1R on the occurrence and development of hepatocellular carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective

          To study the roles of AT1R, PLC-β1, CaM and other related signal molecules in the formation and development of hepatocellular carcinoma (HCC) and their correlation.

          Methods

          ELISA and immunohistochemistry were used to analyze the expressions of target proteins in serum and liver tissue of HCC patients, and the correlation between AT1R, PLC-β1 and CaM and postoperative survival status of patients was followed up and determined. CCK-8 method was used to screen the doses of Ang II and candesartan sensitive to HepG2 and HCCLM3 cells. Transwell experiment was used to observe the effects of different drugs on the migration and invasion activity of HCC cells. Meanwhile, flow cytometry and Western blot were used to detect the expression levels of AT1R, PLC-β1 and CaM in the cells. Then PLC-β1 siRNA was selected to transfect HCC cells, so as to further clarify the mechanism of the above signal proteins. HepG2 cells were inoculated under the hepatic capsule of mice to induce the formation of HCC in situ. Ang II and candesartan were used to stimulate HCC mice to observe the difference in liver appearance and measure the liver index. Finally, ELISA and immunofluorescence experiments were selected to analyze the levels of target proteins in mouse serum and liver tissue.

          Results

          The expression levels of target proteins in serum and liver tissue of HCC patients were significantly increased, and the postoperative survival time of patients with high expression of AT1R, PLC-β1 or CaM was obviously shortened. Ang II and candesartan could significantly promote and inhibit the motility of HCC cells, and had different effects on the levels of AT1R, PLC-β1 and CaM in cells. However, in hepatocellular carcinoma cells transfected with PLC-β1 siRNA, the intervention ability of drugs was obviously weakened. Ang II could significantly promote the formation and progression of mouse HCC, while candesartan had the opposite effect. Meanwhile, medications could affect the expressions of target proteins in mouse serum and liver tissue.

          Conclusion

          AT1R, PLC-β1 and CaM may be risk factors affecting the formation and prognosis of HCC, and the PLC-β1/CaM signaling pathway mediated by AT1R is an important way to regulate the migration and invasion activity of HCC cells.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s12935-021-02261-8.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: not found
          • Article: not found

          World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

          (2013)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues

            The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic parenchymal injury, persistent activation of inflammatory response as well as sustained activation of liver fibrogenesis and wound healing response. Liver fibrogenesis, is a dynamic, highly integrated molecular, cellular and tissue process responsible for driving the excess accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) sustained by an eterogeneous population of hepatic myofibroblasts (MFs). The process of liver fibrogenesis recognizes a number of common and etiology-independent mechanisms and events but it is also significantly influenced by the specific etiology, as also reflected by peculiar morphological patterns of liver fibrosis development. In this review we will analyze the most relevant established and/or emerging pathophysiological issues underlying CLD progression with a focus on the role of critical hepatic cell populations, mechanisms and signaling pathways involved, as they represent potential therapeutic targets, to finally analyze selected and relevant clinical issues.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Liver fibrosis

              Liver fibrosis is a wound-healing response generated against an insult to the liver that causes liver injury. It has the potential to progress into cirrhosis, and if not prevented, it may lead to liver cancer and liver failure. The activation of hepatic stellate cells (HSCs) is the central event underlying liver fibrosis. In addition to HSCs, numerous studies have supported the potential contribution of bone marrow-derived cells and myofibroblasts to liver fibrosis. The liver is a heterogeneous organ; thus, molecular and cellular events that underlie liver fibrogenesis are complex. This review aims to focus on major events that occur during liver fibrogenesis. In addition, important antifibrotic therapeutic approaches and experimental liver fibrosis models will be discussed.
                Bookmark

                Author and article information

                Contributors
                sunwuyi@ahmu.edu.cn
                wwei@ahmu.edu.cn
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                2 November 2021
                2 November 2021
                2021
                : 21
                : 587
                Affiliations
                [1 ]GRID grid.412679.f, ISNI 0000 0004 1771 3402, Department of Emergency Surgery, , The First Affiliated Hospital of Anhui Medical University, ; Jixi Road, Hefei, 230022 Anhui People’s Republic of China
                [2 ]GRID grid.186775.a, ISNI 0000 0000 9490 772X, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, , Anhui Medical University, ; Meishan Road, Hefei, 230032 Anhui People’s Republic of China
                [3 ]GRID grid.186775.a, ISNI 0000 0000 9490 772X, Department of Clinical Medical, , the First Clinical Medical College of Anhui Medical University, ; Meishan Road, Hefei, 230032 Anhui People’s Republic of China
                Author information
                http://orcid.org/0000-0002-6233-2356
                Article
                2261
                10.1186/s12935-021-02261-8
                8561349
                33397383
                65e8be9f-79f7-4569-b61e-db09784a8ea6
                © The Author(s) 2021

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 3 August 2021
                : 11 October 2021
                Funding
                Funded by: the open fund of key laboratory of anti-inflammatory and immune medicine, ministry of education
                Award ID: KFJJ-2020-02
                Award Recipient :
                Funded by: the school fund of anhui medical university
                Award ID: 2020xkj177
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, national natural science foundation of china;
                Award ID: 81673444
                Award Recipient :
                Categories
                Primary Research
                Custom metadata
                © The Author(s) 2021

                Oncology & Radiotherapy
                hepatocellular carcinoma,at1r,plc-β1,cam,migration,invasion
                Oncology & Radiotherapy
                hepatocellular carcinoma, at1r, plc-β1, cam, migration, invasion

                Comments

                Comment on this article